DCF Advisers’s Vir Biotechnology VIR Stock Holding History

DCF Advisers’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-34,500	Closed	-$846K	–	104
2023 Q2	$846K	Buy	+34,500	New	+$866K	0.45%	42

Other funds holding VIR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

DCF Advisers's VIR Position: Q4 2023 in Review

DCF Advisers sold out of Vir Biotechnology (VIR) in Q4 2023, closing a stake of 10,000 shares — an estimated $93.7K sold.

DCF Advisers first reported a position in VIR in Q2 2020 and held it in 11 quarters. The position peaked at $1.44M in Q1 2023. 206 funds tracked by Wall St. Rank hold VIR as of Q4 2023.

DCF Advisers reported no remaining Vir Biotechnology position as of Q4 2023 after selling out during the quarter.
DCF Advisers sold 10,000 Vir Biotechnology shares in Q4 2023, an estimated $93.7K.
DCF Advisers first reported a position in Vir Biotechnology in Q2 2020 and held it in 11 quarters.
DCF Advisers's Vir Biotechnology position peaked at $1.44M in Q1 2023.
206 funds tracked by Wall St. Rank held Vir Biotechnology as of Q4 2023.

Based on DCF Advisers's 13F filing for Q4 2023, filed 13 Feb 2024.